A combination of an anti-CD20 antibody, a P13 kinase-delta selective inhibitor and a BTK inhibitor to treat B-cell proliferative disorders

摘要

(i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; And (iii) at least one Brutonyl tyrosine kinase (BTK) inhibitor, is administered to a subject in need thereof. Kits are also provided for carrying out the claimed method as well as methods for treating B-cell proliferative disorders, such as B-cell hematological malignancies.